⌕
Redhill Biopharma · RDHL · Nasdaq
Tenet — · withheld
Compare
$0.32−7.63%At close
$0.32−0.03 (−7.63%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Redhill Biopharma (RDHL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 100% below its peak, net margin −150.0%.
The four lines that matter · FY21–FY25
Revenue ($K)—
286.0
FY21→FY25CAGR −76.0%/yr
Net income ($K)▲94.8%
−429.0
FY21→FY25CAGR —
Free cash flow ($K)—
—
no FY25 valueCAGR —
Diluted EPS—
0.00
no value for 1 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+0.0%

50.9bn → 50.9bn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)286.0Revenue0.0COGS−2023.0R&D−6172.0SG&A−7942.0Op income7513.0Tax & other−429.0Net income

-150¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
503825130%FY21FY25

Net margin -150.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
286.00.00.061,800.085,757.0—−76.0%
Cost of revenue
0.00.00.033,337.049,406.0——
Gross profit
———28,463.036,351.0——
Research & development
2,023.01,588.03,529.07,279.029,498.0▲27.4%−48.8%
Selling, general & admin
6,172.04,887.06,019.028,586.032,365.0▲26.3%−33.9%
Total operating expenses
8,195.06,475.09,548.071,307.0117,486.0▲26.6%−48.6%
Operating incomefeeds ROC rank
−7,942.0−6,475.0−9,548.0−42,844.0−81,135.0▼22.7%—
Other income, net
−171.06,835.0−8,950.0−28,825.0−16,609.0——
Pretax income
−8,113.0360.0−18,498.0−71,669.0−97,744.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−429.0−8,268.023,916.0−71,669.0−97,744.0▲94.8%—
Per share
Diluted EPSbuyback-sensitive
0.000.00—−0.12−0.21——
Diluted shares (bn)
50.9212.90—1.180.53▲294.8%—
Margins
Gross margin80th pct in Healthcare
———46.1%42.4%——
Operating margin
−2776.9%——−69.3%−94.6%——
Net margin21st pct in Healthcare
−150.0%——−116.0%−114.0%——
FY15 – FY20 · 6 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-27 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Redhill Biopharma's net income?

Redhill Biopharma reported net income of −$429.0K in fiscal 2025, a net margin of −150.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.